# Utah Medical Products, Inc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Utah Medical Products, Inc). ## Overview Utah Medical Products is a U.S.-based medical device company that manufactures and markets specialty products used in obstetrics, gynecology, neonatal care, urology, and other clinical settings. Its business also includes OEM components and assemblies sold to other medical device and non-medical device customers, with operations and sales spanning the United States and selected international markets through direct and distributor channels. ## Products & services • Specialty medical devices for obstetrics, gynecology, neonatal care and urology • Filshie Clip System for female sterilization • OEM components, assemblies and molded parts • Pressure sensor and process control transducer products • Direct sales and distributor-based medical device supply - **Specialty medical devices** (60%) — Finished clinical devices used in obstetrics, gynecology, neonatal care, urology and related procedures. - **Filshie Clip System** (20%) — Tubal ligation and female sterilization products sold directly and through distributors. - **OEM components and assemblies** (15%) — Custom-manufactured parts, molded components and assemblies sold to other manufacturers. - **Biopharma pressure sensing products** (5%) — Pressure sensor and process control transducer configurations for biopharmaceutical applications. - Specialty medical devices for obstetrics, gynecology, neonatal care and urology - Filshie Clip System for female sterilization - OEM components, assemblies and molded parts - Pressure sensor and process control transducer products - Direct sales and distributor-based medical device supply ## Customers UTMD sells to end-user clinical facilities, including hospitals and other medical/surgical care settings, as well as to third-party medical/surgical distributors that support those facilities. It also sells OEM products to other medical device companies, biopharmaceutical manufacturers, and some non-medical device customers that need specialized components. The customer mix reflects a business model built around both direct clinical demand and outsourced manufacturing relationships. - **Clinical facilities** (primary) — Hospitals and end-user medical facilities buy finished devices for direct clinical use and procedural care. - **Medical/surgical distributors** (primary) — Distributors buy and resell devices to clinical facilities, often providing storage and scheduled delivery. - **OEM customers** (primary) — Other device makers buy components, assemblies and molded parts for incorporation into their own products. - **Biopharmaceutical manufacturers** (secondary) — Biopharma customers buy pressure sensor and process control transducer configurations for manufacturing applications. - **Non-medical industrial customers** (secondary) — Selected non-medical customers buy custom components manufactured to specification. - Hospitals and clinical facilities buying specialty devices for procedures - Medical/surgical distributors serving hospitals and stocking facilities - OEM customers sourcing components and assemblies for their own products - Biopharmaceutical manufacturers buying pressure-control transducer products - Non-medical device customers purchasing custom manufactured components ## Geography UTMD sells directly in the United States and also serves Ireland, the UK, France, Canada, Australia and New Zealand through direct and distributor channels. The company also has international manufacturing and intercompany flows, including Filshie device production in Ireland and sales into the U.S. and other overseas markets. Geography matters because the business is exposed to foreign exchange, tariffs, and cross-border distribution economics. - United States is the largest market and a direct-sales base - Ireland is an important manufacturing location for Filshie devices - UK, France, Canada, Australia and New Zealand are direct OUS markets - China distribution creates exposure to shipment timing and tariffs - Cross-border sales and intercompany transfers affect margins and taxes ## Strategy UTMD’s strategy centers on defending its core specialty device franchises, expanding selected product lines, and using its manufacturing base more efficiently across U.S. and international operations. It also seeks to add products through development or acquisition while returning excess cash through dividends and share repurchases when attractive opportunities are limited. - **Defend and support the Filshie Clip System** (short-term) — The product is a core branded franchise and an important contributor to the company’s clinical device mix. - **Grow biopharma transducer sales** (medium-term) — Direct sales to biopharmaceutical manufacturers can diversify the customer base and use pre-qualified status. - **Improve multinational operating efficiency** (medium-term) — Integrated manufacturing and distribution can lower friction across U.S. and OUS operations. - **Return capital and pursue selective acquisitions** (long-term) — The company uses excess cash to support shareholder returns and opportunistic growth. - Defend the Filshie Clip System in the U.S. market - Expand biopharma transducer sales to manufacturers directly - Integrate multinational manufacturing and distribution capabilities - Develop additional clinician-focused products - Use cash for dividends, repurchases and selective acquisitions ## Risks UTMD faces customer concentration risk in OEM and distributor relationships, along with exposure to tariffs, foreign exchange and cross-border shipment timing. As a medical device manufacturer, it also faces regulatory, product liability, quality, and reimbursement-related risks that can affect demand, pricing and operating execution. - **Customer concentration in OEM sales** [high] — A large OEM customer can materially affect revenue when orders decline or are lost. - **Tariff exposure on imported components and devices** [high] — Import duties can increase manufacturing costs and reduce pricing flexibility. - **Foreign exchange and international shipment timing** [medium] — OUS sales are translated into USD and can be delayed by distributor decisions or currency moves. - **Medical device regulatory and product liability risk** [high] — Clinical products require ongoing compliance, quality control and safety performance. - OEM customer concentration can create abrupt revenue declines - Tariffs on imported components and Irish-made devices can raise costs - Foreign exchange moves affect reported OUS sales in USD terms - Distributor shipment timing can shift revenue between periods - Medical device regulation and product liability can disrupt sales ## Accounting Revenue recognition is largely point-in-time when orders are accepted and goods are shipped, but pricing agreements and distributor arrangements can affect timing and comparability across periods. Investors should also watch foreign currency translation, tariff-related cost impacts, and the accounting for intercompany sales that are eliminated on consolidation, especially for Filshie devices manufactured in Ireland and sold into the U.S. - **Revenue recognition timing** — Affects quarterly revenue comparability - **Foreign currency translation** — Affects reported revenue and operating trends - **Intercompany eliminations** — Affects gross sales presentation and consolidated expense structure - **Tariff-related cost accounting** — Affects cost of goods sold and gross margin - Revenue is recognized when fixed-price orders are accepted and shipped - Distributor and facility pricing agreements affect period-to-period comparability - Foreign currency translation affects reported OUS sales in USD - Intercompany Filshie sales are eliminated in consolidation - Tariffs flow through manufacturing costs and can distort gross margin --- *Last updated: 2026-04-29T05:05:56.896503+00:00*